2018
DOI: 10.18632/aging.101478
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: We tested the hypothesis that bevacizumab-induced hypertension may be a useful predictor for objective response rate, progression-free and overall survival in patients with metastatic colorectal cancer via a comprehensive meta-analysis. Search process, article selection and data extraction were independently performed by two investigators. Statistical analyses were conducted using the STATA/SE software. Fourteen independent studies and 2292 study subjects were synthesized. Overall relative risk of objective re… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0
1

Year Published

2019
2019
2022
2022

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 39 publications
(5 reference statements)
0
4
0
1
Order By: Relevance
“…As quantitative proteinuria tests are often conducted as part of daily monitoring of patients treated with these drugs, this result might imply that adverse event monitoring for proteinuria during treatment is important with antiangiogenic drugs. Although hypertension has been reported to be associated with the effectiveness of bevacizumab in patients with CRC [ 39 ] and ramucirumab in patients with gastric cancer [ 40 , 41 ], this association is not unanimously accepted because it has not been reported in patients receiving ramucirumab treatment for CRC [ 42 ]. Because of the nature of retrospective studies, it is not possible to determine whether a causal relationship exists between longer overall treatment duration and proteinuria tests or antihypertensive prescriptions.…”
Section: Discussionmentioning
confidence: 99%
“…As quantitative proteinuria tests are often conducted as part of daily monitoring of patients treated with these drugs, this result might imply that adverse event monitoring for proteinuria during treatment is important with antiangiogenic drugs. Although hypertension has been reported to be associated with the effectiveness of bevacizumab in patients with CRC [ 39 ] and ramucirumab in patients with gastric cancer [ 40 , 41 ], this association is not unanimously accepted because it has not been reported in patients receiving ramucirumab treatment for CRC [ 42 ]. Because of the nature of retrospective studies, it is not possible to determine whether a causal relationship exists between longer overall treatment duration and proteinuria tests or antihypertensive prescriptions.…”
Section: Discussionmentioning
confidence: 99%
“…Platelet levels decreased in two patients and returned to normal without treatment. Some studies have shown that bevacizumab-induced hypertension significantly predicts progression-free survival and overall survival in patients with metastatic colorectal cancer, whereas its prediction for the objective response rate was non-significant ( 47 , 48 ). Previous studies have reported that hypertension may be an indicator of positive antitumor effects, may predict the efficacy of antiangiogenic therapy, and could be associated with a favorable tumor prognosis ( 49 ).…”
Section: Discussionmentioning
confidence: 99%
“…Une relation entre la survenue d'effets indésirables liés au mécanisme d'action des AcM et leur efficacité thérapeutique, en termes de réponse clinique, a été décrite pour les anticorps anti-EGFR [38] et anti-VEGF [39]. Les résultats de ces revues systématiques de la littérature restent cependant discordants, les patients présentant l'effet indésirable ayant une survie (sans progression ou globale) meilleure que les patients n'ayant pas présenté d'effet indésirable.…”
Section: Relation Entre Effets Indésirables Dépendants De La Cible Etunclassified